Skip to content
Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. Veracyte’s common stock is listed on The NASDAQ Global Market under the symbol VCYT.


Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte to Present at the William Blair 38th Annual Growth Stock Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 30, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, will present at the William Blair 38 th Annual Growth Stock Conference on Wednesday, June 13, 2018 at 12:40 p.m.
Toggle Summary Veracyte Announces New Study Published in JAMA Surgery Demonstrates Afirma GSC’s Ability to Significantly Reduce Unnecessary Surgeries in Thyroid Cancer Diagnosis
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 23, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced that clinical validation data published for the first time today – in JAMA Surgery – demonstrate that the next-generation Afirma Genomic Sequencing Classifier (GSC) identifies at least one third


Date Event Details
Summary Toggle Jun 13, 2018 12:40 PM CDT
William Blair 2018 Growth Stock Conference


Bonnie H. Anderson
Chairman of the Board and Chief Executive Officer
Summary Toggle May 23, 2018 9:00 AM EDT
2018 UBS Global Healthcare Conference


Title Documents

Veracyte Corporate Presentation, June 2018